Roth Capital Issues Pessimistic Forecast for TENX Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities research analysts at Roth Capital dropped their FY2025 earnings estimates for Tenax Therapeutics in a report issued on Wednesday, November 12th. Roth Capital analyst J. Aschoff now anticipates that the specialty pharmaceutical company will post earnings of ($1.39) per share for the year, down from their previous estimate of ($1.17). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q4 2025 earnings at ($0.43) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at $1.76 EPS and FY2029 earnings at $3.34 EPS.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings data on Wednesday, November 12th. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.93.

TENX has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Tenax Therapeutics in a report on Tuesday, November 11th. Wall Street Zen raised shares of Tenax Therapeutics to a “sell” rating in a research report on Saturday, October 25th. Guggenheim lowered their price objective on shares of Tenax Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, August 14th. Finally, Piper Sandler initiated coverage on shares of Tenax Therapeutics in a research note on Monday, September 8th. They issued an “overweight” rating and a $20.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Tenax Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Stock Performance

TENX stock opened at $7.68 on Monday. The stock’s 50 day simple moving average is $7.05 and its 200 day simple moving average is $6.32. The company has a market cap of $35.04 million, a P/E ratio of -8.35 and a beta of 1.52. Tenax Therapeutics has a fifty-two week low of $4.63 and a fifty-two week high of $8.24.

Institutional Trading of Tenax Therapeutics

Several institutional investors have recently made changes to their positions in TENX. ADAR1 Capital Management LLC raised its holdings in shares of Tenax Therapeutics by 98.1% in the first quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock valued at $450,000 after purchasing an additional 34,048 shares during the last quarter. Virtu Financial LLC purchased a new stake in Tenax Therapeutics in the 3rd quarter valued at about $92,000. Boothbay Fund Management LLC bought a new position in shares of Tenax Therapeutics during the 3rd quarter worth approximately $2,680,000. Citadel Advisors LLC boosted its stake in shares of Tenax Therapeutics by 318.1% in the 3rd quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company’s stock worth $329,000 after buying an additional 32,908 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Tenax Therapeutics by 34.2% in the 3rd quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company’s stock worth $2,387,000 after buying an additional 79,998 shares during the last quarter. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.